Holen Sie sich die Stockscreener-App
1.75
0.57%
-0.01
Handel nachbörslich:
1.76
0.01
+0.57%
Schlusskurs vom Vortag:
$1.76
Offen:
$1.78
24-Stunden-Volumen:
5,713
Relative Volume:
0.14
Marktkapitalisierung:
$17.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.57M
KGV:
-0.2778
EPS:
-6.3
Netto-Cashflow:
$-38.56M
1W Leistung:
-3.85%
1M Leistung:
-8.85%
6M Leistung:
-52.83%
1J Leistung:
-38.81%
1-Tages-Spanne:
$1.7306
$1.79
1-Wochen-Bereich:
$1.67
$1.87
52-Wochen-Spanne:
$1.00
$5.01
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Firmenname
Sab Biotherapeutics Inc
Sektor
Branche
Telefon
305-845-2813
Adresse
777 W 41ST ST, MIAMI BEACH
Vergleichen Sie SABS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
1.75 | 17.37M | 0 | -45.57M | -38.56M | -6.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-10-09 | Eingeleitet | Craig Hallum | Buy |
| 2024-08-28 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-05 | Eingeleitet | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc Aktie (SABS) Neueste Nachrichten
Millennium Management LLC Decreases Stock Holdings in SAB Biotherapeutics, Inc. (NASDAQ:SABS) - Defense World
Northern Trust Corp Invests $43,000 in SAB Biotherapeutics, Inc. (NASDAQ:SABS) - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Earns “Buy” Rating from Chardan Capital - Defense World
Analysts Offer Predictions for SABS Q2 Earnings - Defense World
SAB Biotherapeutics (SABS) to Release Earnings on Monday - Defense World
HC Wainwright Initiates Coverage on SAB Biotherapeutics (NASDAQ:SABS) - Defense World
Brookline Capital Management Comments on SABS Q2 Earnings - Defense World
SABS Maintains Buy Rating by Chardan Capital with $20 Target | S - GuruFocus
Analysts Are Bullish on Top Healthcare Stocks: Lineage Therap (LCTX), Tenon Medical, Inc. (TNON) - The Globe and Mail
SAB Biotherapeutics (SABS) Receives New "Buy" Rating from Analys - GuruFocus
SAB Biotherapeutics (SABS) Receives Buy Rating and $10 Target fr - GuruFocus
Head to Head Analysis: SAB Biotherapeutics (SABS) and Its Peers - Defense World
SAB BIO (SABS) Reports Cash Decrease as Progress in T1D Therapy Advances | SABS Stock News - GuruFocus
SAB Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates - GlobeNewswire
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Shares Purchased by Geode Capital Management LLC - Defense World
Financial Review: SAB Biotherapeutics (SABS) & The Competition - Defense World
Head-To-Head Review: SAB Biotherapeutics (SABS) versus Its Peers - Defense World
SAB Biotherapeutics (SABS) & Its Peers Head to Head Contrast - Defense World
SAB Biotherapeutics Reports 2024 Financial Results and Advances T1D Therapy - TipRanks
Influenza Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
FY2025 Earnings Forecast for SABS Issued By Chardan Capital - Defense World
HC Wainwright Brokers Boost Earnings Estimates for SABS - Defense World
SAB Biotherapeutics’ (SABS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Price Target Cut to $20.00 by Analysts at Chardan Capital - Defense World
HC Wainwright Reaffirms “Buy” Rating for SAB Biotherapeutics (NASDAQ:SABS) - The AM Reporter
SAB Biotherapeutics price target lowered to $20 from $25 at Chardan - TipRanks
Promising Outlook for SAB Biotherapeutics’ SAB-142: Positive Phase 1 Results and Future Growth Potential Justify Buy Rating - TipRanks
SAB BIO Reports Full Year 2024 Operating and Financial Results - GlobeNewswire
SAB Bio's Diabetes Breakthrough: Phase 1 Success Drives Path to Phase 2b Trials - Stock Titan
SAB Biotherapeutics held cash and equivalents of $20.8 million at end of 2024 - TipRanks
SAB Biotherapeutics, Inc. SEC 10-K Report - TradingView
Financial Contrast: SAB Biotherapeutics (NASDAQ:SABS) versus Kiromic BioPharma (NASDAQ:KRBP) - Defense World
SAB Biotherapeutics (SABS) to Release Earnings on Thursday - Defense World
SAB Biotherapeutics (SABS) Price Target Decreased by 10.00% to 18.36 - MSN
SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Update - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Shares Down 6.7% – Here’s Why - Defense World
SAB BIO announces positive topline Phase 1 clinical results with potentially disease-modifying T1D therapy SAB-142 - News-Medical.Net
Q1 Earnings Estimate for SABS Issued By HC Wainwright - Defense World
SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewswire
Diabetes Treatment Pioneer SAB BIO Sets Stage for Major Investor Presentations - StockTitan
United States shares higher at close of trade; Dow Jones Industrial Average up 0.31% - Investing.com India
Why Is SAB BIO Stock Trading Lower On Tuesday? - Benzinga
SAB BIO Announces Positive Topline Phase 1 Clinical Results - GlobeNewswire
Stock market news: MiNK Therapeutics -93.51%, Revelation Biosciences -93.45% among biggest losers during mid day trading - Business Upturn
SAB Biotherapeutics To Advance SAB-142 Into Phase 2b Trials After Positive Phase 1 Results - Nasdaq
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142 - Marketscreener.com
3 Promising US Penny Stocks With At Least $20M Market Cap - simplywall.st
SAB Biotherapeutics (SABS) Stock Price, News & Analysis - MarketBeat
SAB BIO Announces R&D Webinar Event to Review Phase 1 - GlobeNewswire
SAB BIO to Present Phase 1 Type 1 Diabetes Treatment Data in Upcoming R&D Webinar - StockTitan
Finanzdaten der Sab Biotherapeutics Inc-Aktie (SABS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):